Inflammatory Bowel Diseases
Cure8 research brief
Why This Matters
This study compares two commonly used biologics as first-line therapy for moderate-to-severe ulcerative colitis and reports better short- and long-term effectiveness for vedolizumab with similar safety. The results could inform choices about initial biologic therapy for people newly starting treatment.
Who Should Pay Attention
Biologic‑naïve adult patients with moderate-to-severe ulcerative colitis, gastroenterologists and IBD clinicians deciding first-line biologic therapy, and researchers studying comparative effectiveness of IBD biologics.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a prospective, multicenter real-world comparative study (abstract) that enrolled biologic‑naïve adults with moderate-to-severe ulcerative colitis who started infliximab or vedolizumab between Jan 2023 and Nov 2024. The primary composite outcome combined 14-week clinical remission and 52-week endoscopic remission.
After adjustment using inverse probability weighting, patients starting vedolizumab had higher rates of the composite endpoint and higher clinical and endoscopic remission rates at weeks 14 and 52; adverse event rates were similar. The trial registration (NCT06962020) is provided in the abstract.
Keep In Mind
The content provided is from the journal abstract (structured content depth: abstract). The study used inverse probability weighting to reduce confounding in this observational real-world cohort; as with all nonrandomized studies, residual confounding is possible.
Full-text review of methods and subgroup details (and peer review context) is needed to apply findings to individual treatment decisions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInflammatory Bowel Diseases
PublisherOxford University Press (OUP)
AuthorsDongdong He, Sumei Sha, Xiaolei Liu +9 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 23, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: Chinese Health Promotion Foundation IBD Research Fund Technology, award KYGYJJ-2; Xi’an Municipal Bureau of Science and Technology Medical Research, award 2026JH-YXYM-0016
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Long-term efficacy and safety of vedolizumab compared with infliximab in biologic-naive ulcerative colitis: a systematic review and meta-analysis
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...